

## DAFTAR PUSTAKA

- Akhter, N. *et al.* (2019) 'Determination of Arylamine N-Acetyltransferase 2 Acetylation Genotype by PCR and Phenotyping Using Dapsone Through High-Pressure Liquid Chromatography Assay: A Gender Wise Study', *Dose-Response*, 17(2), pp. 1–10. Available at: <https://doi.org/10.1177/1559325819855537>.
- Alya Andina Dasuki, Annisa Farida Muti, H.Y. (2020) 'Faktor\_resiko\_kejadian\_peningkatan\_kadar\_transmina', *Jurnal Farmasi Indonesia*, Volume 12.
- Annisa, R. and Fridayanti, Z.A.F. (2016) 'Perbedaan Kadar Sgpt Pada Pasien Tuberkulosis Paru Sebelum Dan Sesudah Fase Intensif Di Poliklinik Paru Rsud Arifin Achmad Pekanbaru', *JOM FK*, 3, pp. 1–23.
- Ardiani, T. and Azmi, R.N. (2021) *Identifikasi Kejadian Hepatotoksik pada Pasien Tuberkulosis dengan Penggunaan Obat Anti Tuberkulosis di Rumah Sakit Umum Daerah Abdul Wahab Sjahranie, Borneo Student Research*.
- Clarasanti, I., Wongkar, M.C.P. and Waleleng, B.J. (2016) *Gambaran enzim transaminase pada pasien tuberkulosis paru yang diterapi dengan obat-obat anti tuberkulosis*, *Jurnal e-Clinic (eCl)*.
- Dwi Wahyudi, A. (2015) *Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis*.
- Hussain, Z., Zhu, J. and Ma, X. (2021a) 'Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug', *Drug Metabolism and Disposition*. American Society for Pharmacology and Experimental Therapy, pp. 679–682. Available at: <https://doi.org/10.1124/DMD.121.000389>.
- Hussain, Z., Zhu, J. and Ma, X. (2021b) 'Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug', *Drug Metabolism and Disposition*, 49(8), pp. 679–682. Available at: <https://doi.org/10.1124/dmd.121.000389>.
- Jeong, I. *et al.* (2015) 'Drug Induced Hepatotoxicity of Antituberculosis Drugs and Their Serum Levels', *Chest*, 140(4), p. 771A. Available at: <https://doi.org/10.1378/chest.1116568>.
- Karin A. Mack, Ann Dellinger, and B.A.W. (2017) 'Isoniazid Pathway, Pharmacokinetics (PK)', *Physiology & behavior*, 176(12), pp. 139–148. Available at: <https://doi.org/10.1097/FPC.000000000000232>. PharmGKB.
- Katzung, B.G. (2020) 'Basic and Clinical Pharmacology 14th Edition', *Mehrsys Medical Library* [Preprint].

- Kementrian Kesehatan Republik Indonesia (2020) *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*.
- Kementrian Kesehatan Republik Indonesia (2019) 'Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis', pp. 5–10.
- Kim, I.H., Kisseleva, T. and Brenner, D.A. (2015) 'Aging and liver disease', *Current Opinion in Gastroenterology*, 31(3), pp. 184–191. Available at: <https://doi.org/10.1097/MOG.0000000000000176>.
- Lei, S., Gu, R. and Ma, X. (2021) 'Clinical perspectives of isoniazid-induced liver injury', *Liver Research*. KeAi Communications Co., pp. 45–52. Available at: <https://doi.org/10.1016/j.livres.2021.02.001>.
- Lestari, R.H., Uwan, W.B. and Raharjo, W. (2019) 'Gambaran Kadar Enzim Transaminase Pada Pasien Tuberkulosis Yang Mendapat Terapi Obat Anti Tuberkulosis Di Unit Pengobatan Penyakit Paru-Paru Provinsi Kalimantan Barat', *Jurnal Mahasiswa PSPD FK Universitas Tanjungpura*, 5(1), pp. 2–11.
- Maiti, S. *et al.* (2019) 'Hepatotoxic effect of Rifampicin as an Anti-Tuberculosis drug on male Albino rat', *Journal of Drug Delivery and Therapeutics*, 9(3), pp. 26–32. Available at: <https://doi.org/10.22270/jddt.v9i3.2744>.
- Molla, Y., Wubetu, M. and Dessie, B. (2021) 'Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia', *Hepatic Medicine: Evidence and Research*, Volume 13, pp. 1–8. Available at: <https://doi.org/10.2147/hmer.s290542>.
- Oscanoa, T., Moscol, S. and Amado, J. (2020) 'Características clínicas de la hepatotoxicidad asociada a la pirazinamida en pacientes de un hospital de Lima, Perú', *Revista Peruana de Medicina Experimental y Salud Pública*, 37(3), pp. 516–20. Available at: <https://doi.org/10.17843/rpmesp.2020.373.4684>.
- Peraturan Presiden Republik Indoneisa (2021) *Penanggulangan Tuberkulosis*.
- Pourmohamadi, N. *et al.* (2023) 'Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study', *Iranian Journal of Medical Sciences*, 48(5), pp. 474–483. Available at: <https://doi.org/10.30476/ijms.2023.96145.2765>.
- Rahayu, E.S., Sukeksi, A. and Nuroini, F. (2017) 'Hubungan Kadar SGOT-SGPT Pada Pasien TB Pengobatan Fase Awal Di Puskesmas Pati', *Repository Unimus*, pp. 1–6.
- Rawat, A. *et al.* (2018) 'Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid', *Human and Experimental Toxicology*, 37(4), pp. 373–389. Available at: <https://doi.org/10.1177/0960327117705426>.

- Resky Hevia Lestari, Willy Brodus Uwan, Widi Raharjo (2019). 'Gambaran Kadar Enzim Transaminase Pada Pasien Tuberkulosis Yang Mendapat Terapi Obat Anti Tuberkulosis Di Unit Pengobatan Penyakit Paru-Paru Provinsi Kalimantan Barat' *Jurnal Mahasiswa PSPD FK Universitas Tanjungpura*. 5 (1). pp 2-11.
- Saito, Z. *et al.* (2016) 'Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: A retrospective analysis', *BMC Infectious Diseases*, 16(1), pp. 1–6. Available at: <https://doi.org/10.1186/s12879-016-2000-6>.
- Sarkar, S. and Ganguly, A. (2016) 'Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities', *Mycobacterial Diseases*, 6(2), pp. 1–6. Available at: <https://doi.org/10.4172/2161-1068.1000209>.
- Seri Mahayanti, N.K. and I Putu Alit Sudarsana (2022) 'Laporan Kasus: Drug-induced liver injury pada pasien tuberkulosis relaps', *Intisari Sains Medis*, 13(3), pp. 792–795. Available at: <https://doi.org/10.15562/ism.v13i3.1554>.
- Syalia, T.P., Widada, N.S. and Ritonga, A.F. (2022) 'Pemeriksaan Kadar Sgot-Sgpt Pada Lansia Penderita Tuberkulosis', *Binawan Student Journal*, 4(1), pp. 9–13. Available at: <https://doi.org/10.54771/bsj.v4i1.215>.
- Sunarmi, S. and Kurniawaty, K. (2022) 'Hubungan Karakteristik Pasien Tb Paru Dengan Kejadian Tuberkulosis', *Jurnal 'Aisyiyah Medika*, 7(2), pp. 182–187. Available at: <https://doi.org/10.36729/jam.v7i2.865>.
- Titan Meliana P. and Widodo. (2021). 'Kadar SGOT, SGPT, Bilirubin Total Pada Pasien Tuberkulosis Paru' *Jurnal Laboratorium Medis*. 3 (1)
- U.S. Department of Health and Human Services (2017) 'Common Terminology Criteria for Adverse Events (CTCAE) v.5.0', *Cancer Therapy Evaluation Program (CTEP)*, p. 155. Available at: [https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/ctcae\\_v5\\_quick\\_reference\\_5x7.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf).
- Wesnawa, M.A.D.P. and Kusmiati, T. (2020) 'Drug Induced Hepatitis pada Tuberkulosis Paru dengan Multisite Tuberkulosis Ekstraparu', *Jurnal Respirasi*, 5(2), p. 34. Available at: <https://doi.org/10.20473/jr.v5-i.2.2019.34-40>.
- WHO (2022) *Global Tuberculosis Report*. Available at: <http://apps.who.int/bookorders>.